

PSIL

AdvisorShares Psychedelics ETF

Analyst Report

PSIL is actively managed to provide exposure to the emerging global psychedelics industry.

ESG Themes and Scores

N/A

ESG Rate

N/A

Global Percentile

N/A

Peer Percentile

Performance Data

	PSIL	ETF Database Category Average	Factset Segment Average
1 Month	-2.13%	3.56%	-0.48%
3 Month	10.78%	3.73%	1.36%
YTD Return	15.03%	2.81%	2.20%
1 Year Return	57.00%	26.42%	22.94%
3 Year Return	7.73%	7.04%	2.39%
5 Year Return	N/A	0.44%	0.00%

Top 5 Holdings

Symbol	Holding	% Assets
CMPS	COMPASS Pathways Plc Sponsored ADR	11.06%
ATAI	AtaiBeckley Inc.	9.31%
DFTX	Definium Therapeutics, Inc.	8.80%
RLMD	Relmada Therapeutics Inc	7.81%
NRXP	NRX Pharmaceuticals, Inc.	7.08%

Vitals

Issuer	AdvisorShares
Brand	AdvisorShares
Structure	ETF
Expense Ratio	1.00%
Inception	Sep 15, 2021
Index Tracked	N/A

ETF Database Themes

Category	Health & Biotech Equities
Asset Class	Equity
Asset Class Size	Multi-Cap
Asset Class Style	N/A
Region (General)	Global
Region (Specific)	Broad

FactSet Classifications

Segment	Equity: Global Pharma, Biotech & Life Sciences
Category	Sector
Focus	Health Care
Niche	Pharma, Biotech & Life Sciences
Strategy	Active
Weighting	Proprietary

